Use of circulating tumor DNA to predict survival in patients with resected high-risk stage II/III melanoma.

Rebecca J. Lee,Gabriela Gremel,Andrea Marshall,Kevin Alan Myers,Nita Fisher,Philippa Corrie,Janet A. Dunn,Nathalie Dhomen,Mark R. Middleton,Richard Marais,Paul Lorigan

Use of circulating tumor DNA to predict survival in patients with resected high-risk stage II/III melanoma.

2017

Rebecca J. Lee
Gabriela Gremel
Andrea Marshall
Kevin Alan Myers
Nita Fisher
Philippa Corrie
Janet A. Dunn
Nathalie Dhomen
Mark R. Middleton
Richard Marais
Paul Lorigan

9583Background: Patients with high-risk stage II/III resected melanoma commonly develop metastatic disease. Adjuvant high dose interferon and ipilimumab 10mg/kg are associated with survival benefit...

Keywords:

Melanoma
Circulating tumor DNA
Cancer research
Pathology
Medicine
Adjuvant
Interferon
Oncology
stage ii
in patient
Internal medicine
Ipilimumab
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations